TMEM106A is downregulated in NSCLC. Overexpression reduces proliferation, migration, invasion, and induces apoptosis. TMEM106A also reverses EMT (↑E‐cadherin, ↓N‐cadherin, and vimentin) and inhibits the PI3K–Akt–NFκB pathway. Here, CDH17 is linked to non-small cell lung carcinoma.